The approvals were granted to HEC Pharm, Biocon and Sun Pharmaceutical.
MS is a chronic, inflammatory autoimmune disease that disrupts communication between the brain and other parts of the body.
The most common side effects of Gilenya are headache, elevated liver enzymes, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain and pain in the extremities.
The drug also comes with some serious risks, including slowed heart rate — especially after the first dose — serious infection, vision problems, swelling or narrowing of blood vessels in the brain, respiratory problems, liver injury or skin cancer.
It could also harm developing fetuses, so women taking Gilenya or generic versions are advised to use effective contraception.
Patients should be monitored for serious infection during treatment and for two months after discontinuing treatment.
Read the full news release here.
More articles on pharmacy:
‘We’re training our kids for jobs that won’t exist’: Community Health Systems director of pharmacy on the industry’s changing landscape
How 5 health systems are using their 340B savings
Partnerships are key to Walgreens’ survival, CEO says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
